|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Comparison analysis between haplo identical stem cell transplantation and matched sibling donor stem cell transplantation for high-risk acute myeloid leukemia in first complete remission显示文摘In order to compare the effect between haploidentical(HID) stem cell transplantation(HSCT) and matched sibling donor(MSD)stem cell transplantation for high-risk acute myeloid leukemia(AML) in first complete remission status(CR1), we retrospectively studied 170 cases who received stem cell transplantation from Jan 2008 to Jul 2015 in Peking University People's Hospital. We divided all cases into MSD group(43 cases) and HID(127 cases) group. Patients in HID and MSD group displayed similar baseline characteristics except for age distribution. There were no statistic differences for overall survival(OS), cumulative incidence of relapse, leukemia free survival(LFS), transplantation related mortality(TRM) between HID and MSD group. The 3-year OS, LFS for all patients was 63.9% and 59.7% respectively. Multivariate analysis showed that grade III-IV acute graft versus host disease(aGVHD) was an independent risk factor for treatment related mortality(HR=8.134, 95% CI:3.210–20.611, P<0.001), monosomy/complex chromosomal karyotype and white blood cell count more than 50×109 L-1 were two independent factors for relapse(HR=1.533, 95% CI: 1.040–2.260, P=0.031)(HR=1.004, 95% CI: 1.001–1.008, P=0.015).Grade III-IV aGVHD was an independent factor for mortality(HR=3.184, 95% CI: 1.718–5.902, P<0.001). These results demonstrated some risk factors for high-risk AML leukemia transplantation and indicated for AML patients in CR1 status, haplo stem cell transplantation could have the same therapeutic effect as MSD transplantation. | Yang Liu Xiaojun Huang Qian Fei Lanping Xu Xiaohui Zhang Kaiyan Liu Yuhong Chen Huan Chen Yu Wang | 2019 | Science China(Life Sciences)2019，62，5： | 9 |
| 2 | Modification of donor lymphocyte infusion: how to improve the outcome?显示文摘(HSCT),which has been acknowledged as a curative procedure,relapse of leukemia remains the leading cause of death following transplantation and is a disappointment to transplant physicians.Leukemic relapse occurs due to leukemia cell escape from immune-mediated killing (immune escape) by pre-transplantation conditioning and post-transplantation immune control.Immune exhaustion of donor T cells is one of the common causes of relapse,and donor lymphocyte infusions (DLIs) have the potential to reverse this immune exhaustion.Patients who are deemed eligible for intensive treatment at this point are offered either DLI or a second transplant.Contrary to the contemporary understanding,DLI results in the same response and survival obtained via a second transplant but with less toxicity (Kharfan- Dabaja et al.,2018).Starting in the mid-1990s,our group along with few others demonstrated the efficacy of DLI,which was initially confirmed by the Hadassah group in Jerusalem in the late 1980s.In the first four patients (with both acute and chronic leukemias) treated by us with DLI,the initial success rate was 100%,which encouraged us to pursue this treatment further. | Yu Wang Lanping Xu Chenhua Yan Xiaojun Huang | 2019 | Science China(Life Sciences)2019，62，9： | 5 |
| 3 | Reduced β2-GPI is associated with increased platelet aggregation and activation in patients with prolonged isolated thrombocytopenia after allo-HSCT显示文摘We aimed to measure platelet function and its relationship with β2-GPI in prolonged isolated thrombocytopenia(PT) after allogeneic hematopoietic stem cell transplantation(allo-HSCT).Fifty-six patients with PT and 60 allo-HSCT recipients without PT(non-PT controls) were enrolled.Platelet aggregation and activation,β2-GPI and anti-β2-GPI antibody levels,vWF antigen,and vWF activity were analyzed.The effect of β2-GPI on platelet aggregation was also measured ex vivo.Results showed that ADP-induced platelet aggregation significantly increased(39%±7.5% vs.23%±8.5%,P=0.032),and the platelet expression of both CD62 p(33.6%±11.6% vs.8.5%±3.5%,P<0.001) and PAC-1(42.4%±7.6% vs.6.8%±2.2%,P<0.001) was significantly higher in patients with PT than in those without PT.Significantly lower β2-GPI levels(164.2±12 μg m L^-1 vs.234.2±16 μg mL^-1,P<0.001),higher anti-β2-GPI IgG levels(1.78±0.46 U mL^-1 vs.0.94±0.39 U mL^-1,P<0.001),and increased vWF activity(133.06%±30.50% vs.102.17%±25.90%,P<0.001) were observed in patients with PT than in those without PT.Both ADPinduced platelet aggregation(n=116,r^2=-0.5042,P<0.001) and vWF activity(n=116,r^2=-0.2872,P<0.001) were negatively correlated with β2-GPI levels.In summary,our data suggested that platelet aggregation and activation were significantly higher in patients with PT than in those without PT,which might be associated with reduced β2-GPI levels.The reduced β2-GPI levels might be due to the existence of anti-β2-GPI IgG. | Haixia Fu Jingzhong Zhao Lanping Xu Kaiyan Liu Yu Wang Huan Chen Wei Han Jingzhi Wang Fengrong Wang Xiaojun Huang Xiaohui Zhang | 2019 | Science China(Life Sciences)2019，62，7： | 4 |
| 4 | 血小板输注无效在慢性粒-单核细胞白血病患者异基因造血干细胞移植后的发生率及临床意义显示文摘目的分析血小板输注无效在慢性粒-单核细胞白血病(CMML)患者异基因造血干细胞移植(allo-HSCT)后的发生率及其临床意义。方法回顾性分析2004年至2021年在北京大学血液病研究所接受allo-HSCT后的55例CMML患者, 根据移植后30 d内是否发生血小板输注无效分为血小板输注无效组和血小板输注有效组, 比较两组造血重建、移植相关并发症及移植后1年生存情况。结果①55例CMML患者中, 男28例(50.9%), 女27例(49.1%), 中位年龄为44(12~63)岁。②14例(25.5%)患者移植后发生血小板输注无效, 41例(74.5%)患者血小板输注有效。③血小板输注无效组血小板植入率明显低于血小板输注有效组(28.6%对100%, χ^(2)=26.835, P<0.001), 血小板植入的中位时间分别为67(33~144)d、21(9~157)d(χ^(2)=2.696, P=0.010)。血小板输注无效组、有效组急性移植物抗宿主病(aGVHD)和慢性移植物抗宿主病(cGVHD)发生率差异无统计学意义(χ^(2)=3.399, P=0.183;χ^(2)=1.573, P=0.455)。④血小板输注无效组、有效组移植后1年总生存(OS)率分别为(35.4±13.9)%、(75.1±7.8)%(χ^(2)=4.366, P=0.037), 无白血病生存(LFS)率分别为(28.1±13.3)%、(65.3±8.2)%(χ^(2)=3.226, P=0.072), 移植相关死亡率(TRM)分别为(48.2±2.4)%、(9.0±0.25)%(χ^(2)=4.747, P=0.009)。⑤血小板输注无效组移植后出血事件发生率高于血小板输注有效组[35.7%(5/14)对4.9%(2/41), χ^(2)=6.934, P=0.009]。结论 CMML患者allo-HSCT后血小板输注无效发生率为25.5%, 显著影响血小板植入率和植入速度, 且移植后出血事件发生率增加、OS率降低、TRM增高。 | 赵晨 赵晓甦 王昱 闫晨华 许兰平 张晓辉 刘开彦 黄晓军 孙于谦 | 2022 | 中华血液学杂志2022，43，9： | 0 |
| 5 | Influence of the degree of donor bone marrow hyperplasia on patient clinical outcomes after allogeneic hematopoietic stem cell transplantation显示文摘This study evaluated the influence of the degree of donor bone marrow(BM)hyperplasia on patient clinical outcomes after allogeneic hematopoietic stem cell transplantation(allo-HSCT).Twelve patients received allo-HSCT from hypoplastic BM donors between January 2010 and December 2017.Forty-eight patients whose donors demonstrated BM hyperplasia were selected using a propensity score matching method(1:4).Primary graft failure including poor graft function and graft rejection did not occur in two groups.In BM hypoplasia and hyperplasia groups,the cumulative incidence(CI)of neutrophil engraftment at day 28(91.7%vs.93.8%,P=0.75),platelet engraftment at day 150(83.3%vs.93.8%,P=0.48),the median time to myeloid engraftment(14 days vs.14 days,P=0.85)and platelet engraftment(14 days vs.14 days,P=0.85)were comparable.The 3-year progression-free survival,overall survival,CI of non-relapse mortality and relapse were 67.8%vs.71.7%(P=0.98),69.8%vs.77.8%(P=0.69),18.5%vs.13.6%(P=0.66),and 10.2%vs.10.4%(P=0.82),respectively.In multivariate analysis,donor BM hypoplasia did not affect patient clinical outcomes after allo-HSCT.If patients have no other suitable donor,a donor with BM hypoplasia can be used for patients receiving allo-HSCT if the donor Complete Blood Count and other examinations are normal. | Feifei Tang Xiaodong Mo Xiaohui Zhang Yu Wang Chenhua Yan Yuhong Chen Huan Chen Wei Han Yao Chen Fengrong Wang Jingzhi Wang Yuqian Sun Yuanyuan Zhang Kaiyan Liu Xiaojun Huang Lanping Xu | 2020 | Science China(Life Sciences)2020，63，1： | 0 |
| 6 | 潍坊地区血小板输注无效患者抗体鉴定与分析显示文摘目的:初步探讨潍坊地区发生血小板输注无效患者的血小板抗体类型。方法:排除非免疫因素,采用PAKPLUS试剂盒对2012年8月~2013年2月的89例发生血小板输注无效的患者进行血小板相关抗体的鉴定,分析HLA-I类抗体与HPA抗体的分布情况,评价抗体阳性患者进行配合性血小板输注后的效果。结果:89例患者中,81例检测出HLA-Ⅰ类抗体和(或)HPA抗体,其中只有HLA-Ⅰ类抗体阳性48例(53.94%),只有HPA抗体阳性22例(24.72%),两类抗体均呈现阳性11例(12.36%);均未检出两类抗体8例(8.99%);对33例HPA抗体阳性患者中,GPⅡb/Ⅲa抗体共29例(35.80%),GPIa/Ⅱa抗体共21例(25.93%),GPIb/Ⅸ抗体共7例(8.64%),GP IV抗体共4例(4.94%);HLA-Ⅰ类抗体或HPA阳性抗体患者中女性为47例,男性为34例,差异有统计学意义;81例抗体阳性患者经输注配合性血小板后均为有效性输注。结论:潍坊地区血小板输注无效患者中主要为HLA-I类抗体,阳性抗体在女性群体中所占比例要高于男性群体,抗体阳性患者经输注配合性血小板后均为有效性输注。 | 孙福廷 王立萍 姜坤 韩海峰 赵月凯 吴晓春 | 2021 | 医学检验与临床2021，32，9： | 0 |
| 7 | 移植前血液形态学完全缓解状态对单倍型相合造血干细胞移植治疗B-ALL预后的影响显示文摘目的探讨接受单倍型相合造血干细胞(Haplo-SCT)的B细胞系急性淋巴细胞白血病(B-ALL)患者移植前血液学缓解(HCR)状态对预后的影响。方法回顾性分析2012年9月至2016年6月北京大学血液病研究所接受Haplo-SCT且移植前均获得HCR的317例B-ALL患者。采用Cox模型分析移植前HCR状态对317例接受Haplo-SCT的B-ALL患者预后的影响。结果 317例患者3年非复发死亡(NRM)、累计复发(CIR)、无病生存(LFS)及总生存(OS)率分别为15%、15%、71%和74%。HCR伴外周血中性粒细胞(ANC)和血小板(PLT)恢复(CR)组、ANC未恢复伴或不伴PLT恢复(CRi)组和ANC恢复伴PLT未恢复(CRp)组的3年NRM、CIR和LFS率的差异均无统计学意义(P均>0.05);CR组患者3年OS率高于CRi组(76%vs 59%,P=0.049)。移植前微小残留病(P=0.006)和慢性移植物抗宿主病(GVHD)(P=0.020)影响CIR;PLT植入影响NRM、LFS和OS(P值均<0.001);Ⅲ~Ⅳ度急性GVHD影响NRM(P<0.001)和OS(P=0.035);慢性GVHD影响LFS(P<0.001)。结论移植前HCR状态不影响接受Haplo-SCT的B-ALL患者的预后。 | 王志东 刘艳荣 王亚哲 韩伟 陈欢 陈瑶 王景枝 莫晓冬 张圆圆 闫晨华 孙于谦 陈育红 王昱 许兰平 张晓辉 刘开彦 黄晓军 常英军 | 2019 | 临床检验杂志2019，37，11： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员